Biotia Competitors and Similar CompaniesClear all
Biotia's competitors and similar companies include Cardiosense, WISEDON, iamYiam and Novadiscovery.
 Biotia Biotia is a health tech company using sequencing and proprietary bioinformatics technology to reduce hospital-acquired infections. |  WISEDON WISEDON is a company that develops online platforms to support the use of multicriteria decision support models. |  Novadiscovery Novadiscovery is a health tech company that develops a hybrid approach combining mechanistic models and artificial intelligence to de-risk research programs and optimize clinical development. | |||
Founding Date | Founding Date 2016 | Founding Date 2020 | Founding Date 2016 | Founding Date 2016 | Founding Date 2010 |
Type | Type Private | Type Private | Type Private | Type Private | Type Private |
Tags | |||||
Locations | Locations New York, US HQ | Locations Chicago, US HQ | Locations Lisboa, PT HQ | Locations London, GB HQ | Locations Lyon, FR HQ |
Employees | Employees 26 | Employees 333% increase | Employees N/A | Employees 294% increase | Employees 61 |
Funding | |||||
Latest funding round | Latest funding round $ 2.4m (over 6 years ago) | Latest funding round $ 15.1m (over 3 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 2.4m | Total funding raised $ 15.1m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Cardiosense
HQ
Chicago, US
Employees
33↑ 3% increase
Cardiosense is a company that develops cardiac care solutions.
View companyWISEDON
HQ
Lisboa, PT
WISEDON is a company that develops online platforms to support the use of multicriteria decision support models.
View company
iamYiam
HQ
London, GB
Employees
29↑ 4% increase
iamYiam is a company that provides a health platform.
View companyNovadiscovery
HQ
Lyon, FR
Employees
61
Novadiscovery is a health tech company that develops a hybrid approach combining mechanistic models and artificial intelligence to de-risk research programs and optimize clinical development.
View company